Primary diffuse large B‐cell lymphoma of the tonsil

Abstract

The combination of palladium complex (tBu3P)Pd(Me)Cl (1) and NaB[3,5‐(CF3)2C6H3]4 (NaBAr4) catalyzed homopolymerization of a novel monomer, norbornene (NB) with a pendent 2‐fluorosulfonyltetrafluoroethoxymethyl chain (NBSF). Catalytic activities of 1/NaBAr4 were higher than those of previously reported palladium or nickel catalysts, probably, because the palladium center with electron donative tBu3P ligand was barely poisoned by the sulfonyl fluoride coordination. Thus, 1/NaBAr4 is the current best catalyst system for NBSF polymerization. The catalyst system also gave copolymers of NB with NBSF. The obtained copolymers have high sulfonyl‐fluoride incorporation and a narrow molecular weight distribution. Present catalyst system could control incorporation ratio of NBSF by changing a feed monomer ratio with slow addition of NB solution. © 2008 Wiley Periodicals, Inc. J Polym Sci Part A: Polym Chem 46: 5133–5141, 2008

Analysis of treatment outcomes for primary tonsillar lymphoma

“…With regard to tonsillar lymphoma, a few studies have reported that higher radiation doses result in better local control and overall survival (OS). However, the therapeutic effects of RT and the optimal RT dose require further evaluation with respect to tonsillar lymphoma [2,13,14]. …”

Primary mantle cell lymphoma of tonsil: Case report

“…Примарни тонзиларни лимфом чини мање од 1% малигнитета главе и врата;. NHL усне шупљине и орофарингса чине 13% свих примарних екстранодалних NHL 3,4 . Већина тонзиларних лимфома је пореклом B-ћелија и дифузни великоћелијски B-лимфом је најчешћи 67%-96%, следи MCL са 10%.…”

“…Већина ових пацијената има локализовану болест 6,7,8,9 , стадијум 1 или 2. Код пацијената са раним стадијумом болести без обимних маса, петогодишње преживљавање је 65%-85% 3,8,10,11 . Успех лечења зависи од откривања болести управо у раним стадијумима.…”

Dosimetric and Clinical Outcomes With Intensity Modulated Radiation Therapy After Chemotherapy for Patients With Early-Stage Diffuse Large B-cell Lymphoma of Waldeyer Ring

“…High levels of local control and favorable survival can be achieved for patients with localized WR-DLBCL using combined modality therapy (11,(15)(16)(17). However, the role of consolidation radiotherapy for specific cohorts of DLBCL patients is controversial because of radiotherapy-related, late side-effects (15,(18)(19)(20).…”